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Abstract  
Background: Application of high power radiofrequency (RF) energy for a short duration 
(HPSD) to isolate pulmonary vein (PV) is an emerging technique. But power and duration 
settings are very different across different centers. Moreover, despite encouraging preclinical 
and clinical data, studies measuring acute effectiveness of various HPSD settings are limited.  
Methods: Twenty-five consecutive patients with symptomatic atrial fibrillation (AF) were 
treated with pulmonary vein isolation (PVI) using HPSD. PVI was performed with a contact 
force catheter (Thermocool SF Smart-Touch) and Carto 3 System. The  following parameters 
were used: energy output 50 W, target temperature 43°C, irrigation 15 mL/min, targeted 
contact force of > 10 g. RF energy was applied for 6 to 10 s. Required minimal interlesion 
distance was 4 mm. Twenty minutes after each successful PVI adenosine provocation test 
(APT) was performed by administrating 18 mg adenosine to unmask dormant PV conduction.  
Results: All PVs (100 PVs) were successfully isolated. RF lesions needed per patient were 
131 ±  41, the average duration for each RF application was 8.1 ± 1.7 s. Procedure time was 
138  ±  21 min and average of total RF energy duration was 16.3 ±  5.2 min and average 
amount of RF energy was 48209 ± 12808W s. APT application time after PVI was 31.1 ± 8.3 
min for the left sided PVs and 22.2 ± 4.6 min (p = 0.005) for the right sided PVs. APT was 
transiently positive in 18 PVs (18%) in 8 (32%) patients. 
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Conclusions: Pulmonary vein isolation with high power for 6–10 s is feasible and shortens 
the procedure and ablation duration. However, acute effectiveness of the HPSD seems to be 
lower than expected. Further studies combining other ablation parameters are needed to 
improve this promising technique.  
Key words: ablation, atrial fibrillation, reconnection, adenosine, high power 
 
 
Introduction 
Since the pioneering study of Haissaguerre et al. [1] demonstrating pulmonary vein 
(PV) as the main source for atrial fibrillation (AF), pulmonary vein isolation (PVI) with either 
radiofrequency (RF) energy or cryo-balloon is widely used in treatment of AF. Nevertheless, 
in 30–50% of cases AF recurs despite complete electrical disconnection of the PVs. The 
major cause of recurrence is reconnection of the initially isolated PVs. Indeed, 80% of the 
patients with recurrence of AF demonstrate at least one reconnected PV [2, 3]. Thus, 
successful ablation outcomes require durable lesion formation which depends on the RF 
current delivered, the duration of RF energy delivered, the contact force applied on the tissue 
and stability of the ablation catheter. On the other hand, some safety concerns arise regarding 
collateral tissue damage, like esophageal injury. In recent years, a new technique of applying 
high power RF energy in short duration (HPSD) had been introduced. Most of the data about 
HPSD technique is derived from ex vivo and in vivo studies which have consistently shown 
sufficient lesion formation and fewer complications with the HPSD technique compared to 
conventional lower power and longer duration techniques (30–40 W for 30 s) [4, 5]. So far, 
limited non-randomized clinical data have shown promising results regarding arrhythmia-free 
survival with the HPSD technique [6–9]. Nevertheless, there is no consensus about the power 
and duration settings for HPSD, whereas energy levels above 40 W are considered as high 
power and duration of application for 6–10 s as short duration.  
The acute effectiveness of a PVI can be evaluated with an adenosine provocation test 
(APT), which unmasks dormant PV conduction after apparently successful PVI [2]. Two 
major trials analyzed APT guided PVI to enhance outcome with conflicting results about its 
utility [10, 11]. Nevertheless, APT is the only method in determining at least the acute 
effectiveness of an ablation technique during PVI procedure.  
Knowing that there is no consensus about the optimal HPSD settings and that there are 
very limited data which evaluated acute efficiency of any HPSD techniques, this acute study 
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was performed using APT to evaluate the acute efficiency of lesions created with the HPSD 
settings which are in use at the documented institution.  
 
Methods 
Patient population 
Consecutive ablation naïve patients with symptomatic paroxysmal or persistent AF 
were enrolled in this prospective observational registry. The study complied with the 
Declaration of Helsinki and the protocol was approved by the ethical commission of the 
University of Regensburg. Informed consent was obtained from all patients.  
Inclusion criterion was paroxysmal or persistent symptomatic AF with an indication 
for PVI according to current AF classification criteria [2].  
 
Ablation procedure 
A left atrial thrombus was excluded in all patients before the procedure using 
computerized tomography. In only one patient, a transesophageal echocardiography had been 
performed to exclude left atrium (LA) thrombus because of inconsistent tomography result. 
Using the tomography data, the left atrial anatomy was extracted with help of the Carto Merge 
software (Biosense Webster Inc., Diamond Bar, CA, USA) and defined the PV anatomy of 
each patient including accessory PVs or left main trunks before the ablation procedure.  
The ablation procedure was performed under continued oral anticoagulation, in deep 
analgosedation or general anesthesia. After venous access, a double transseptal puncture was 
performed using the Brockenbrough technique.  Asteerable sheath was used (DireX, Boston 
Scientific, Malborough, MA, USA) to guide the ablation catheter. Activated clotting time was 
kept between 300 and 350 s.  
A circumferential mapping catheter (LassoNav) and a 3.5 mm ablation catheter 
(Navistar Thermocool Smart Touch SF; Biosense Webster Inc., Diamond Bar, CA, USA) 
were placed in the LA. An electroanatomic map of the LA was created with the Carto 3 
System using a fast automated mapping tool (Version 6, Biosense Webster Inc., Diamond 
Bar, CA, USA). Antral PVI with RF ablations applied only round the PV ostia of the 
ipsilateral PVs was performed without ablations taken between the ipsilateral PVs.  Obtaining 
a contact force of 10–15 g on the posterior wall and 15–20 g on the anterior wall was tried. 
The applied RF energy was 50 W at each point with a temperature limit of 43°C and a saline 
irrigation rate of 15 mL/min. The minimum duration of each application was 6–10 s, 
depending on the stability and contact force applied as determined by the physician. Keeping 
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the inter-lesion distance by 4–6 mm, as measured by the dedicated tool of the Carto system 
was tried.  
Pulmonary vein isolation was confirmed with demonstration of input into and exit 
block out of the PV. During ablation around the PV, the PV signals in the Lasso catheter were 
monitored continuously; after the disappearance of PV signals meaning input block,  
stimulation from inside the ipsilateral PV was performed with the ablation catheter using 
maximal output of the cardiac stimulator to confirm exit block from the PV. When local PV 
capture was not successful with the ablation catheter or if there was no cross-talk between the 
ipsilateral PVs, then  each PV was separately stimulated from all the electrodes of the Lasso 
catheter sequentially  
 
Adenosine provocation test 
For each PV, adenosine provocation test was performed by administering 18 mg 
adenosine bolus intravenously 20–40 min after successful isolation to unmask the dormant 
PV conduction. In patients with left main trunks, it was performed for each arm of the 
distal PV an APT separately. Before APT, spontaneous recovery of the PV was excluded 
with the lasso catheter by checking for entrance and exit block. After administration of 
adenosine, intracardiac recordings were continuously monitored. Adenosine effect was 
recognized when at least one P wave was not conducted due to atrioventricular block. In 
the case of ineffectiveness of 18 mg adenosine, the test was repeated with doubling of the 
adenosine dose. PV reconnection was diagnosed when the circular mapping catheter 
detected PV potentials in a previously isolated PV. A PV reconnection was classified as 
temporary if the PV signals disappear again when the effect of adenosine diminished or as 
permanent if the PV signals persisted.  
 
Follow-up 
As this is an acute study, the patients were followed-up for only 4 weeks after the 
PVI to exclude rare complications such as esophageal injury, which may occur 2–4 weeks 
after PVI. No data about the rhythm state had been collected as the patients were in the 
blanking period after PVI.  
 
Control group: 
   Results were compared from the current study with a patient collective from a 
previous study, where conventional RF ablation was compared with visually guided laser 
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balloon ablation [12]. In that study the RF arm, PV isolation was performed by creating a 
circumferential ablation with ablation at the carina when needed using conventional 
settings (30 W at the posterior wall and 40 W at the anterior wall of the PV with a duration 
of 30 s for each RF application).  
 
Statistical analysis 
Values are distributed as means ± standard deviation for normally distributed 
continuous variables, median and interquartile range (IQR) for skewed distributions (assessed 
by means of the Kolmogorov-Smirnov one sample test) and counts and percentages for 
categorical variables. Statistical analysis was conducted using the Student t-test (unpaired) for 
continuous variables with normal distribution and the Mann-Whitney U test for variables with 
non-normal distribution. The chi-square test or the Fisher exact test was used to compare the 
categorical variables in different groups. Statistical significance was defined as p < 0.05. 
Statistical analysis was performed using SPSS 25 (SPSS Inc., Chicago, IL, USA).  
 
Results 
Patient population 
A total of 25 consecutive patients were included. The clinical characteristics are 
summarized in Table 1. 
 
Procedural data 
The average procedure time was 138 ± 21 min and fluoroscopy duration and doses 
were 13.2 ± 6.8 min and 1182 ± 314 cGy, respectively. Only 2 (8%) patients had left main 
trunk with distally separated PVs.  A separate APT in patients with a left main trunk was 
also performed, two PV  were also calculated in these patients. All of the PVs in 25 
patients were isolated successfully using 131 ± 41 RF lesions. Average duration of ablation 
energy application was 16.3 ± 5.2 min and average amount of applied RF energy was 
48209 ± 12808 W. Ablation duration per point was 8.1 ± 1.7 s on average (Table 2).  
Mean contact force was 14.25 ± 2.70 g. Lesions created with suboptimal contact 
force, defined as applied force less than 10 g, were in the minority with 5.2% of all the 
ablation lesions, as depicted in the figure.  
Twenty-four (96%) of the 25 left sided PV pairs and 22 (88%) of the right sided PV 
pairs had been isolated after completion of the first ablation circle, in the other patients a 
conduction gap was sought to isolate the PVs.  
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Entrance and exit block could be demonstrated in all PVs; local capture from the 
ipsilateral PV was successful in 90 (90%) PVs. In 10 (10%) PVs there was no cross talk; in 
these PVs exit block could be demonstrated by stimulation with the lasso catheter in each 
PV.  
 
Adenosine provocation test  
All isolated PVs underwent an APT. In 3 (12%) patients for the left sided PVs and 
in 6 (24%) for patients  of the right sided PVs, additional RF ablation after the first 
successful isolation had to be performed because of spontaneous reconnection detected 
before APT to re-isolate the PVs.  
Time to APT was longer for the left sided PVs compared to the right sided PVs 
(31.1 ± 8.3 min vs. 22.2 ± 4.6 min, p = 0.005).  
An Adenosine provocation test was positive in 8 (32%) patients. Reconnection was 
detected in 9 PV pairs (3 left sided and 6 right sided PV). All of the reconnections were 
transient and disappeared with the cessation of the adenosine effect. Only one patient had a 
transient reconnection in all PVs.  
 
Differences in clinical and procedural parameters in APT positive and negative patients 
Clinical characteristics of patients with or without reconnection did not differ (each 
p = NS). Only a minority of the patients had general anesthesia (4 patients, 16%). None of 
the patients with general anesthesia had a reconnection. Also, a spontaneous reconnection 
detected just before the APT did not negatively influence the final APT result after re-
isolation (p = 0.25). There were also no differences in the total number of RF applications, 
applied RF energy, ablation duration as well as in the mean contact force in PVs with 
reconnection and without reconnection; as shown in the Table 3.  
 
Comparison with a historical control group using conventional ablation settings 
The  control group consisted of 25 patients (65 ± 11 years) with paroxysmal AF. 
Ninety-eight percent of the PVs could be isolated successfully (right inferior PV cannot be 
isolated due to esophagus temperature rise). Procedure time (237 ± 60 min vs. 138 ± 21 
min, p = 0.001) and ablation duration (60.2 ± 17.2 min vs. 16.3 ± 5.2 min, p < 0.001) were 
significantly longer and total applied ablation energy (227000 ± 67000 W vs. 48209 ± 
12808 W, p < 0.001) was significantly higher in the former conventional study group in 
comparison to the current HPSD group. Despite the fact that significantly more ablation 
 7 
energy was applied in the conventional group, the first pass isolation rate was significantly 
lower than in the current study (48% to 92%, p < 0.001). Moreover, in the conventional RF 
ablation group, significantly more PV showed dormant reconnection than in the current 
study (29 PVs vs. 18 PVs, 31% vs. 18%, p = 0.04). 
 
Complications 
There were no acute severe complications after the procedure such as stroke or 
TIA, pericardial tamponade, phrenic nerve paralysis or procedure related death. Two (8%) 
patients developed light groin hematomas requiring manual compression. In the short 
follow-up period of four weeks, none of the patients developed an atrial esophageal fistula 
or complaints suggesting esophageal injury.  
 
Discussion 
The main finding of the present study is that using RF energy of 50 W for 6–10 s 
ablations is feasible and effective in successfully isolating the PV, but with an acute 
reconnection rate in 18% in 32% of the patients. As expected, the total procedure time was 
shorter (138 ± 21 min) when compared to a recent study which used conventional ablation 
settings with and without ablation index (AI) data, 192 ± 42 min and 149 ± 33 min, 
respectively [2]. There were no severe acute and late complications at four weeks, which 
could be attributed to the high-power ablation.   
The  high power RF energy in short duration technique is being used increasingly 
worldwide in recent years [6–9]. The proposed main advantage of HPSD technique is its 
ability to destroy the tissue by using the resistive heating which occurs at the very 
beginning of the RF application [4, 5, 13]. During high power ablation, keeping the 
application time very short — around 5 s as applied in the most in and ex vivo studies— 
limits the conductive heating phase of the ablation injury leading to lesions with 
comparable sizes but which are less deep as compared to conventional low power long 
duration (the 25–30 W for 30 s ablations) technique. As the lesion depth is less, the risk of 
producing collateral injury on the esophagus or the phrenicus nerve should be unlikely. 
Bhaskaran et al. [4] showed that 50 W ablations for 5 s produced transmural lesions 
without overheating of the tissue and thus avoiding stem pops. In their in vivo studies they 
showed that lesion width with 40 W/30 s ablations were larger than with 50 W/5 s but stem 
pop rate was also high 10.5%, whereas no stem pop occurred with 50 W/5 s. Borne et al. 
[5] also showed that HPSD technique produces lesions with similar volumes but with less 
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depth than low power ablations. They elegantly showed that any increase in power settings 
(doubling of power increases lesion volume by 6.7) is much more effective than any 
increase in duration (the doubling of duration increases lesion volume by 2.2) [5].  
Despite the benefits shown in ex- and in vivo studies, clinical trials showing the 
acute effectiveness with the HPSD technique in the left atrium are limited. Moreover, there 
is also no consensus about the optimum power and duration settings for HPSD ablations. 
Kanj et al. [6] compared 50W ablations during PVI with 35 W ablations and found a better 
6-month outcome (82% vs. 66%) with 50 W. But they also noticed more stem pops and 
pericardial effusions in the 50 W group, as they did not shorten the ablation duration with 
50 W and ablated as usual for at least 30 s [6]. Bunch et al. [7] described a so-called 
“painting” technique where they moved the catheter back and forth while ablating with 50 
W. They reported 85% freedom from AF at 1-year without adverse effects and 
complication due to high power [7]. Of note, these two trials are from an era where contact 
force catheters were not available. The first study with HPSD ablation using contact force 
comes from Winkle at al. [8]. Using the EnSiteTM VelocityTM platform and St. Jude 
TacticathTM open irrigated-tip contact force catheter, they delivered 50 W ablations. The 
duration of ablation (mean 11.2 ± 3.7 s) was determined either by pacing loss or by 
achievement of a target lesion size index of 5.5–6. They reported a freedom from AF 86% 
and 83% at 1 year, in patients with paroxysmal and persistent AF, respectively [8]. As 
expected, both procedure (101 ± 19.7 min) and total RF energy time (895 ± 258 s) were 
very short and there were no complications reported. The largest clinical data about HPSD 
technique comes again from Winkle at al. [9]. They analyzed complication rates in 13974 
patients who underwent PVI with high power in four centers from 2006 till 2017. The 
ablation settings varied significantly with RF powers 45–50 W and duration ranging from 
2 to 10 s. They concluded that 45–50 W ablations for short durations can be performed 
with very low complication rates [9].  
In the documented clinic herein, 50 W had been chosen as the high-power energy 
level, as this is the safest energy level creating sufficient lesion size according to in-vitro 
studies [4, 5]. Also, the duration of the application was chosen according to the above-
mentioned studies. The minimum duration of ablation in vitro studies was 5 s; thus, to 
compensate for the delay of the ablation generator in generating the desired power in vivo, 
we decided to apply ablation energy for a minimum of 6 s at each site [4]. We stopped the 
energy application at 10 s, according to the data shown by Winkle et al. [9]. Despite the 
present strict ablation protocol, the acute reconnection rate, which was the main objective 
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of the study, was higher than expected. A 18% reconnection rate in 32% of patients is 
rather comparable with older studies when reconnection rates were evaluated with APT 
before the contact force era [14, 15]. Andrade et al. [16] showed several years ago a 
reconnection rate of 8% in 16% of the patients with PVI using contact force catheters 
compared to 35% reconnection in 50% the patients ablated with standard RF catheters.  
These results are consistent with the data from the present study with conventional 
ablation settings [12]. Compared with the current study, the reconnection rate was higher, 
whereas the first pass isolation rate with conventional settings was strikingly lower in the 
conventional ablation group despite using a much higher amount of ablation energy and 
longer ablation duration [12]. This means that applying more energy in total but with a 
lower maximal power and with less catheter stability during the necessarily longer ablation 
time is less efficient in lesion formation.    
The mean contact force in the current study was 14.2 ± 2.7g and thus apparently 
sufficient according the EFFICAS I study data, which showed at least 10 g contact force 
should be applied to improve ablation success [17]. Moreover, ablations with suboptimal 
contact force defined as < 10 g were at a minimum level (5.2%) in the present study. 
Interestingly, the ablation duration (8.1 ± 1.7 s) in the present study was lower than in the 
study by Winkle et al. (11.2 ± 3.7 s) [8]. On the other hand, it cannot be said that the 
ablation lesions created in the current study were not effective because there was a very 
high first pass isolation rate (90% for the left and 85% for the right PVs) which is closely 
comparable with the elegantly designed study by Phlips et al. [18]. In their CLOSE-guided 
PVI concept, Phlips et al. [18] compared the efficacy and safety of a PVI protocol using 
the combination of contact force, interlesion distance and AI with the conventional 
ablation technique using just contact force. The ablation energy was just 35 W. The first 
pass isolation rate was 58% for the conventional group, and 96% for the CLOSE-guided 
group, slightly better than in the present study [18]. Importantly, the acute reconnection 
rate of 3% was very low in their CLOSE-guided group.  
In the light of these data it seems that the lesions created with the HPSD strategy 
are at first effective, but this effect is not long lasting since APT after the PVI was positive 
in 18% of the PVs. One explanation could be the very short duration of the RF applications 
in the current study. Longer applications, even if only just a few seconds more, might be 
needed even in the HPSD technique creating sufficient lesions. Since AI incorporates 
various parameters such as contact force, applied power and stability, the duration of 
application is dependent on these parameters. Using AI data, in combination with HPDS 
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strategy, could create more sufficient lesions, with longer or even shorter ablation duration, 
dependent on the AI. 
At the start of this study a decision was made not to use the AI parameter because at 
that time, there was no clinical or in vitro about using AI in high power and short duration 
ablation. Also, there were some safety concerns coming from the developing company 
(Biosense Webster) because of a lack of data. Recently, two studies showed better outcomes 
with high power energy applications using AI data. Chen et al. [19] showed promising data 
with a first-round PVI of 92% using 50 W limited by an AI value of 550 at the anterior and 
400 at the posterior wall. Preliminary clinical results were also very promising with 96% 
freedom of AF. Unfortunately, they did not use the adenosine test to evaluate acute 
effectiveness of PVI with their ablation settings [19]. Okamatsu et al. [20] compared the acute 
effectiveness of the HSPD with low and medium power settings in a non-randomized manner. 
Each group consisted of 20 patients. In the low and medium power groups, the ablation 
energy was 30 W at the anterior and 20 W at the posterior wall and 40 W and 30 W, 
respectively. In the high power group, it was 50 W at the anterior and 40 W at the posterior 
wall. AI was again different in this study; 400 at the anterior, 360 at the posterior and 260 at 
the esophagus. The high-power group had the best first-pass isolation rate (85%) with no 
reconnection after APT (0%). Again, in these studies the AI targets and the RF power settings 
were different, thus a direct comparison could not be performed [20].  
According to the present data, it can be concluded that ablation with HPSD using only 
the duration criteria (6–10 s) alone seems not very effective, at least in an acute phase, and 
combining the HSPD with AI parameter might improve the efficiency of this technique. There 
is great need for further studies to determine the most effective and safe settings for this 
promising technique.  
 
Limitations of the study 
This is a small, non-randomized, single-center study with a low number of patients, 
but with a very impressive end point, which was not expected. No significant differences 
were found when comparing clinical and procedural data in APT positive and negative 
groups. The reason for this could be the low number of patients, making statistical tests 
difficult to perform.  
Again, the small number of patients in the present study makes it difficult to make 
firm conclusions but there are some interesting findings which should be investigated in 
studies with more patients. Such as that all four patients with general anesthesia did not 
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have reconnection under adenosine gives the impression that general anesthesia could be 
helpful in creating consistent lesions, as shown by Di Biase et al. [21]. 
Although no complications occurred, such as phrenicus nerve damage or atrial-
esophageal fistula which could be attributed to high power ablation, it is difficult to conclude 
that high power ablation with 50 W is safe due to the small number of patients. Moreover,  no 
esophageal temperature monitoring during or gastroscopy after ablation was performed, thus 
no real safety data is available from the present study. On the other hand, till now other 
studies using high power did not report complications due to high power energy [9].  
 
Conclusions 
Pulmonary vein isolation using the HPSD technique with energy output of 50 W for 
6 to 10 s is feasible but acute effectiveness was lower than expected, thus this promising 
technique needs to be further optimized using additional ablation parameters such as an 
ablation index.  
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Figure 1. Percentage of the ablation application by average contact force ranges. Contact 
force < 10 g as suboptimal was defined 
 
Percent of ablations per each contact force range 
 
 
Table 1. Clinical characteristics. 
Number of patients 25 
Age [years] 62.7 ± 10.6 (range 31–80) 
Gender male 16 (64%) 
Body mass index 27.1 ± 4.1 (range 21.0–35.9) 
Paroxysmal AF 19 (76%) 
Persistent AF 6 (24%) 
Duration of AF [years] 3.1 ± 1.5 (range 0.5–7.0) 
CHA2DS2-VASc score 2.5 (0–6) 
Left atrial size [mm] 41.7 ± 5.4 (34–58) 
Left atrial volume [mL] 35.6 ± 13.2 (19–57) 
LVEF [%] 57 ± 10 (range 30–70) 
Hypertension 13 (52%) 
Diabetes mellitus 3 (12%) 
Sleep apnea syndrome 2 (8%) 
 14 
Coronary artery disease 5 (20%) 
Dilated cardiomyopathy 1 (4%) 
Prior stroke/transient ischemic attack 1 (4%) 
Previous antiarrhythmic drugs failed 7 (28%) 
AF — atrial fibrillation; LVEF — left ventricular ejection fraction 
 
Table 2. Procedural data. 
Total procedure duration [min] 138 ± 21 
Total fluoroscopy duration [min] 13.2 ± 6.8 
Total radiation dose [cGy] 1182 ± 314 
Total ablation count 131 ± 41 
Total ablation duration [min] 16.3 ± 5.2 
Total ablation energy[W] 48209 ± 12808 
Ablation duration per lesion [s] 8.1 ± 1.7 
Contact force [g] 14.2 ± 2.7 
PVs 100 
Successful isolation [%] 100 
Isolation with first circle (left side) 24 (96%) 
Isolation with first circle (right side) 22 (88%) 
Time to APT (left side) [min] 31.1 ± 8.3 
Time to APT (right side) [min] 22.2 ± 4.6 
Reconnected PV (left side) 6 (6%) 
Reconnected PV (right side) 12 (12%) 
Patients with reconnected PVs 8 (32%) 
APT — adenosine provocation test; PV — pulmonary vein 
 
Table 3. Comparing ablation data between adenosine provocation test (APT) positive and 
negative pulmonary vein. 
Parameters APT negative APT positive P 
Ablation count 59 ± 17 60 ± 21 0.55 
Ablation duration [min] 8.1 ± 4.6 7.7 ± 2.3 0.44 
Ablation energy [W] 21716 ± 6255 22201 ± 6594 0.77 
Contact force [g] 14.5 ± 3.4 14.1 ± 4.9 0.16 
 
